Anemia Clinical Trial
Official title:
Role of Vitamin E in Enhancing Erythropoiesis and the Molecular Mechanism of the Action of Vitamin E on Erythropoietin-secreting Cells
Anemia is one of the major health problems of the developing countries of the world [1].
According to the WHO reference criteria, an adult is labeled as anemic, if the blood
hemoglobin concentration falls below 13.0 g/dL in men or less than 12.0 g/dL in the
non-pregnant women [2]. Hemoglobin concentrations below the lower limit of normal are a
common laboratory finding in apparently healthy people in general population all over the
world [3-5]. Many of these mildly anemic individuals are not investigated sufficiently to
establish the probable cause of their anemia and thus may end up with morbidity and health
problems, especially the young women in developing countries [4].
Only few studies on the use of vitamin E in the correction of anemia have been published and
hardly any on correction of mild anemia in healthy adults. The objective of this
intervention study was to investigate the association of vitamin E supplementation with
post-supplemental blood hemoglobin levels in mildly anemic healthy Pakistani adults.
Anemia is one of the major health problems of the developing countries of the world [1].
According to the WHO reference criteria, an adult is labeled as anemic, if the blood
hemoglobin concentration falls below 13.0 g/dL in men or less than 12.0 g/dL in the
non-pregnant women [2]. Hemoglobin concentrations below the lower limit of normal are a
common laboratory finding in apparently healthy people in general population all over the
world [3-5]. Many of these mildly anemic individuals are not investigated sufficiently to
establish the probable cause of their anemia and thus may end up with morbidity and health
problems, especially the young women in developing countries [4].
A few human studies during the past few years have suggested the possible use of antioxidant
vitamins in the correction of anemia [6]. Vitamin E is an essentially required lipophilic
vitamin with a variety of antioxidant and non-antioxidant functions. It has been shown that
treatment with vitamin E resulted in increased number of colony forming units of erythroid
precursors in experimental animals and protected their bone marrow against drug- induced
toxicity [7]. In some of the clinical trials in patients with hematological disorders,
vitamin E supplementation showed decrease in red blood cell deformability and enhanced blood
hemoglobin levels [8,9]. Although clinical benefits of vitamin E on increasing hemoglobin
levels in some disease states have been published, yet its effect on a presumably healthy
adult population with no abnormality other than mild anemia has hardly been reported.
Hypothesis:
Vitamin E supplementation for three months to mildly anemic healthy adults (with no past
history of any iron supplements) would result into improved post-supplemental levels of
blood hemoglobin compared to their basal levels.
Objective of the present study: To investigate the association of vitamin E supplementation
in mildly anemic healthy adults with the post-supplemental blood hemoglobin levels in a
general population of Karachi, Pakistan.
Study Participants
In this placebo-controlled and single blinded study, 357 healthy volunteer subjects, 235
males and 122 non-pregnant females of age 18-45 years were recruited and enrolled through
general practitioners' (GP) clinics from various localities of Karachi and from the
personnel of the Aga Khan University, Karachi. The recruitment was started in 2008 and
completed in 2011. The clinical examination of study subjects was carried out by a general
physician. The participants were nonsmokers; had no history of gastrointestinal disorders or
chronic disease or iron deficiency during the last 6 months; had not taken vitamin E
supplements or received blood transfusion during the past 6 months, and were not dehydrated.
They were screened for the presence of mild anemia (10.0-13.9 g/dL, in males and 8.4-11.2
g/dL, in non-pregnant females using the criteria followed by the Aga Khan University
Hospital (AKUH), Karachi.
After screening, 124 subjects (80 males and 44 females) who were found to be mildly anemic
and fulfilling the criteria were included in the intervention trial. Eighty two subjects
were randomly placed in Intervention group and 42 in the Control group.
Supplementation
Intervention group: Each subject was provided with 400 mg oral capsule of vitamin E (Evion,
containing dl-alpha tocopheryl acetate) and was asked to take one capsule daily continuously
for three months.
Control group: Each subject was provided with placebo (edible oil) capsules to be taken once
daily for three consecutive months. The placebo capsules were identical to vitamin E
capsules in size, shape, color, appearance and taste. The compliance of the participants was
monitored by counting the number of capsules consumed after every 4 weeks.
Blood Sampling and Measurement of Biomarkers
Ten mL of fasting blood was collected before the start of supplementation from each
participant and another sample (10 mL) was obtained after 3 months of supplementation. Each
blood sample was divided into two equal parts; one part of blood was transferred to a tube
containing anticoagulant , while the other part was transferred to a plain tube for
obtaining serum. Blood samples were analyzed for blood hemoglobin levels in an automated
hematology analyzer. Serum/plasma samples were kept frozen at -70 degree Centigrade for
analysis of other biomarkers.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
| Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
| Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
| Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
| Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
| Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
| Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
| Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
| Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |